CA2931779C - Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof - Google Patents

Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof Download PDF

Info

Publication number
CA2931779C
CA2931779C CA2931779A CA2931779A CA2931779C CA 2931779 C CA2931779 C CA 2931779C CA 2931779 A CA2931779 A CA 2931779A CA 2931779 A CA2931779 A CA 2931779A CA 2931779 C CA2931779 C CA 2931779C
Authority
CA
Canada
Prior art keywords
antibody
antibodies
cell
seq
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2931779A
Other languages
English (en)
French (fr)
Other versions
CA2931779A1 (en
Inventor
Sydney Welt
David Kostyal
Rachel S. Welt
Virginia RAYMOND
Jonathan A. Welt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WELT BIO-MOLECULAR PHARMACEUTICAL LLC
Original Assignee
WELT BIO-MOLECULAR PHARMACEUTICAL LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WELT BIO-MOLECULAR PHARMACEUTICAL LLC filed Critical WELT BIO-MOLECULAR PHARMACEUTICAL LLC
Publication of CA2931779A1 publication Critical patent/CA2931779A1/en
Application granted granted Critical
Publication of CA2931779C publication Critical patent/CA2931779C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2931779A 2013-12-03 2014-12-01 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof Active CA2931779C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911186P 2013-12-03 2013-12-03
US61/911,186 2013-12-03
PCT/US2014/067957 WO2015084736A2 (en) 2013-12-03 2014-12-01 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Publications (2)

Publication Number Publication Date
CA2931779A1 CA2931779A1 (en) 2015-06-11
CA2931779C true CA2931779C (en) 2023-04-25

Family

ID=53274268

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2931779A Active CA2931779C (en) 2013-12-03 2014-12-01 Antibodies targeting b-cell receptor complex membrane bound igm and uses thereof

Country Status (9)

Country Link
US (2) US9926381B2 (https=)
EP (1) EP3077010B1 (https=)
JP (1) JP6535668B2 (https=)
CN (1) CN106456809B (https=)
AU (2) AU2014357450B2 (https=)
CA (1) CA2931779C (https=)
IL (1) IL245880B (https=)
SG (1) SG10201709164UA (https=)
WO (1) WO2015084736A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020127827A1 (de) * 2018-12-20 2020-06-25 Ava Lifescience Gmbh Verfahren zur selektion biologischer bindemoleküle

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2100892T3 (es) * 1989-09-15 1997-07-01 Tanox Biosystems Inc Tratamiento de enfermedades autoinmunitarias.
IE903280A1 (en) 1989-09-15 1991-07-17 Akzo Nv Compartmentalized container for a plurality of small¹articles
EP1941275B1 (en) * 2005-09-29 2013-07-24 Medimmune, Inc. Method of identifying membrane lg specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
CA2651178A1 (en) * 2006-05-03 2007-11-05 Sydney Welt Immunoglobulin associated cell-surface determinants in the treatment of b-cell disorders
PE20081216A1 (es) * 2006-09-01 2008-09-04 Therapeutic Human Polyclonals Inc Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos
KR20090105913A (ko) * 2006-11-02 2009-10-07 다니엘 제이 카폰 이동 부분을 갖는 하이브리드 면역글로불린
EP1972640A1 (en) * 2007-03-23 2008-09-24 Biomay AG Apoptosis inducing antibodies
WO2011064758A2 (en) * 2009-11-30 2011-06-03 Pfizer Limited Fusion protein
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides

Also Published As

Publication number Publication date
IL245880A0 (en) 2016-07-31
WO2015084736A2 (en) 2015-06-11
WO2015084736A4 (en) 2016-02-25
WO2015084736A3 (en) 2016-01-21
SG10201709164UA (en) 2017-12-28
AU2019229346A1 (en) 2019-10-03
US20160304625A1 (en) 2016-10-20
EP3077010B1 (en) 2020-04-01
EP3077010A4 (en) 2017-08-02
AU2014357450B2 (en) 2019-10-03
US10227419B2 (en) 2019-03-12
EP3077010A2 (en) 2016-10-12
JP2016540504A (ja) 2016-12-28
JP6535668B2 (ja) 2019-06-26
CN106456809B (zh) 2020-02-07
US9926381B2 (en) 2018-03-27
US20180186895A1 (en) 2018-07-05
CA2931779A1 (en) 2015-06-11
CN106456809A (zh) 2017-02-22
IL245880B (en) 2020-09-30
AU2014357450A1 (en) 2016-07-14

Similar Documents

Publication Publication Date Title
CN104013957B (zh) 用新的抗il13单克隆抗体治疗癌症
US20100136030A1 (en) Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
CN120365432A (zh) 双特异性抗体
US10227419B2 (en) Antibodies targeting B-cell receptor complex membrane bound IgM and uses thereof
US8163497B2 (en) Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
AU2013201832C1 (en) Anti-extended type I glycosphingolipid antibody, derivatives thereof and use
HK1201457B (en) Treatment of cancer with novel anti-il 13 monoclonal antibodies
HK1157363B (en) Anti-extended type i glycosphingolipid antibody, derivatives thereof and use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241126

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241126

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251119

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251119